Sunshine Biopharma (SBFM) Operating Margin (2015 - 2026)

Sunshine Biopharma has reported Operating Margin for 10 years, with the latest figure at 17.25% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin fell 270.0% year-over-year to 17.25%; the trailing twelve-month figure through Mar 2026 stood at 17.83% (down 207.0% YoY), and the FY2025 full-year result was 17.15%, down 49.0% from the prior year.
• Operating Margin for Q1 2026 stood at 17.25%, up from 20.87% in the prior quarter.
• The five-year high for Operating Margin was 11.54% in Q3 2025, with the low at 1293.58% in Q3 2022.
• Historically, Operating Margin has averaged 210.77% across 5 years, with a median of 18.23% in 2023.
• The largest YoY upside for Operating Margin was 218701 bps in 2022 against a maximum downside of 30847 bps in 2022.
• Sunshine Biopharma's Operating Margin stood at 593.01% in 2022, then jumped by 97 bps to 15.46% in 2023, then tumbled by 37 bps to 21.24% in 2024, then gained by 2 bps to 20.87% in 2025, then gained by 17 bps to 17.25% in 2026.
• The last three Operating Margin figures came in at 17.25% (Q1 2026), 20.87% (Q4 2025), and 11.54% (Q3 2025), per Business Quant data.